WO2023136797A3 - A bilayer tablet composition comprising amorphous dapagliflozin and metformin - Google Patents
A bilayer tablet composition comprising amorphous dapagliflozin and metformin Download PDFInfo
- Publication number
- WO2023136797A3 WO2023136797A3 PCT/TR2023/050022 TR2023050022W WO2023136797A3 WO 2023136797 A3 WO2023136797 A3 WO 2023136797A3 TR 2023050022 W TR2023050022 W TR 2023050022W WO 2023136797 A3 WO2023136797 A3 WO 2023136797A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- metformin
- bilayer tablet
- tablet composition
- amorphous dapagliflozin
- composition
- Prior art date
Links
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 title abstract 2
- 229960003834 dapagliflozin Drugs 0.000 title abstract 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title abstract 2
- 239000007916 tablet composition Substances 0.000 title abstract 2
- 229960003105 metformin Drugs 0.000 title 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 229960004329 metformin hydrochloride Drugs 0.000 abstract 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a bilayer tablet composition comprising metformin hydrochloride and amorphous dapagliflozin, and at least one pharmaceutically acceptable excipient, wherein both layers comprising microcrystalline cellulose as a filler and at least one pharmaceutical acceptable excipient. Also, the composition has immediate release layer and an extended release layer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2022000397 | 2022-01-13 | ||
| TR2022/000397 TR2022000397A2 (en) | 2022-01-13 | A TWO-LAYER TABLET COMPOSITION CONTAINING AMORPHOUS DAPAGLIFLOZIN AND METFORMIN |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2023136797A2 WO2023136797A2 (en) | 2023-07-20 |
| WO2023136797A3 true WO2023136797A3 (en) | 2023-08-17 |
Family
ID=87278498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2023/050022 WO2023136797A2 (en) | 2022-01-13 | 2023-01-11 | A bilayer tablet composition comprising amorphous dapagliflozin and metformin |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023136797A2 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011060256A2 (en) * | 2009-11-13 | 2011-05-19 | Bristol-Myers Squibb Company | Bilayer tablet formulations |
| WO2013137839A1 (en) * | 2012-03-15 | 2013-09-19 | Ali Raif İlaç Sanayi Ve Ticaret Anonim Şirketi | Tablet formulation comprising dapagliflozin and extended release metformin |
| WO2020009352A1 (en) * | 2018-07-06 | 2020-01-09 | 한미약품 주식회사 | Pharmaceutical preparation containing amorphous dapagliflozin l-proline, and preparation method therefor |
-
2023
- 2023-01-11 WO PCT/TR2023/050022 patent/WO2023136797A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011060256A2 (en) * | 2009-11-13 | 2011-05-19 | Bristol-Myers Squibb Company | Bilayer tablet formulations |
| WO2013137839A1 (en) * | 2012-03-15 | 2013-09-19 | Ali Raif İlaç Sanayi Ve Ticaret Anonim Şirketi | Tablet formulation comprising dapagliflozin and extended release metformin |
| WO2020009352A1 (en) * | 2018-07-06 | 2020-01-09 | 한미약품 주식회사 | Pharmaceutical preparation containing amorphous dapagliflozin l-proline, and preparation method therefor |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023136797A2 (en) | 2023-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019060322A3 (en) | High dosage valbenazine formulation and compositions, methods, and kits related thereto | |
| BRPI0513909A (en) | multi-layer pharmaceutical tablet for controlled release of active ingredients with highly ph-dependent solubility | |
| IL179454A (en) | Coated tablet formulation comprising saxagliptin and method for preparing the same | |
| WO2009006095A3 (en) | Dual portion lozenge dosage form | |
| WO2011039768A3 (en) | Pharmaceutical compositions for reducing alcohol-induced dose dumping | |
| UA86831C2 (en) | Extended release tablet formulation comprising pramipexole or pharmaceutically acceptable salt thereof, method for its manufacturing and administration | |
| RU2712757C3 (en) | TWO-LAYER TABLET COMPOSITION | |
| AU2010308458A8 (en) | Orally transformable tablets | |
| WO2007079390A3 (en) | Medicament for topical use | |
| IL197574A0 (en) | Pharmaceutical compositions | |
| WO2004064815A8 (en) | Oral dosage formulation | |
| NO20084065L (en) | Quick-release paracetamol tablets | |
| WO2009043926A3 (en) | Oral fast disintegrating tablets | |
| WO2009059701A3 (en) | Sustained release tablets with hydromorphone | |
| WO2008152398A3 (en) | Formulations for inhalation | |
| WO2009038412A3 (en) | Beta-secretase inhibiting compounds | |
| WO2010012459A3 (en) | A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms | |
| SI1994926T1 (en) | Valsartan formulations | |
| WO2023136797A3 (en) | A bilayer tablet composition comprising amorphous dapagliflozin and metformin | |
| ATE479427T1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING CANDESARTAN-CILEXETIL | |
| WO2010005148A3 (en) | Novel isoindolinone derivatives having inhibitory activity against t-type calcium channel and method for preparation thereof | |
| MX2023012535A (en) | Effervescent oral composition. | |
| WO2022080986A8 (en) | Glp-1/gip dual agonist, long-acting conjugate thereof, and pharmaceutical composition comprising same | |
| EP1584335A3 (en) | Active substance combination comprising a carbinol composition and an opioid | |
| WO2011018185A3 (en) | Pharmaceutical tablet comprising rosuvastatin calcium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 202491509 Country of ref document: EA |
|
| ENP | Entry into the national phase |
Ref document number: 16563 Country of ref document: GE |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |